Navigation Links
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Date:6/2/2009

eatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer.

In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma. Micromet also has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target.

Micromet's pr
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
2. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
3. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
4. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
5. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
6. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
7. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
8. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
9. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
10. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
11. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  Personal Genome Diagnostics Inc. (PGDx), ... methodologies and expertise in genomic analysis of defined ... collaboration with Blueprint Medicines.  PGDx is an innovator ... alterations in tumors, and Blueprint Medicines is an ... a genetically defined patient population. "This ...
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
(Date:5/21/2013)... PathoGenetix, Inc., a commercial-stage developer of ... today that it has successfully identified and strain typed ... from the Centers for Disease Control and Prevention (CDC) ... findings are detailed in a poster presented ... Microbiology in Denver on Monday. , The 250 E. ...
(Date:5/20/2013)... UAE (PRWEB) May 21, 2013 ... consultancy specializing in “game-changing” life science and health related ... Dalia Dergham to its International Project Team. Dergham's expertise ... even greater multi-cultural depth to Grace Century as it ... the globe. , Ms. Dergham holds both an under ...
Breaking Biology Technology:Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... TORONTO, ON - Quantum mechanics is famous for saying that ... there doesn,t make a sound. Quantum mechanics also says that ... tree. And so the famous paradox: how can we ... An international team of researchers, led by University ...
... Genentech and Novartis have the best image among ... market research consultancy that recently completed its 2011 MSImage ... corporate equity and R&D attributes to determine which measures ... growing marketplace. Amgen, Sanofi-aventis and Eli ...
... 2, 2011 Morphotek®, Inc., a subsidiary of Eisai ... phase II study of MORAb-004 for the treatment of ... first-in-class monoclonal antibody that specifically binds to endosialin/tumor endothelial ... safety and therapeutic activity at two dosages. ...
Cached Biology Technology:U of T scientist leads international team in quantum physics first 2U of T scientist leads international team in quantum physics first 3Genentech and Novartis Remain Image Leaders in Oncology and Hematology 2Genentech and Novartis Remain Image Leaders in Oncology and Hematology 3Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 3
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
(Date:5/20/2013)... Minnesota Medical School researchers from the Masonic Cancer Center, ... Tumor Program, have developed a new mouse model of ... to discover new genes and gene pathways driving this ... week in the journal Nature Genetics . , ... lab of David Largaespada, Ph.D., professor in the Medical ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2
... combined with an immune-boosting substance called an adjuvant, ... strain of avian influenza (H9N2) provoked a strong ... by the National Institute of Allergy and Infectious ... Health. , The clinical trial of 96 adults ...
... brain cells on a new three-dimensional scaffold of tiny ... body than any other cell culture system. , An ... may one day replace the ubiquitous Petri dish for ... ONE. Shuguang Zhang, associate director of MIT's Center for ...
... Peering deep within the cells of fruit flies, developmental ... University in Philadelphia may have discovered a new way ... If they're right, and the same processes are at ... eventually have implications for improving the understanding of a ...
Cached Biology News:H9N2 avian flu vaccine paired with adjuvant provokes strong human immune response at low doses 2MIT creates 3-D scaffold for growing stem cells 2MIT creates 3-D scaffold for growing stem cells 3Jefferson researchers uncover new way nature turns genes on and off 2
...
...
... 48° Fixed Angle Polypropylene Rotor ... Series, IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. ... quiet operation. /MP4, ,EXCLUSIVE polypropylene rotor ... can be repeatedly autoclaved. Polypropylene ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
Biology Products: